<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AJA</journal-id>
<journal-id journal-id-type="hwp">spaja</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Alzheimers Dis Other Demen</journal-id>
<journal-title>American Journal of Alzheimer's Disease &amp; Other Dementias®</journal-title>
<issn pub-type="ppub">1533-3175</issn>
<issn pub-type="epub">1938-2731</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1533317512465667</article-id>
<article-id pub-id-type="publisher-id">10.1177_1533317512465667</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Thoughts, Opinions and Controversies</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Direct Thrombin Inhibitors’ Potential Efficacy in Alzheimer’s Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Rami</surname>
<given-names>Bou Khalil</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1533317512465667"/>
<xref ref-type="corresp" rid="corresp1-1533317512465667"/>
</contrib>
</contrib-group>
<aff id="aff1-1533317512465667">Psychiatric Hospital of the Cross, Saint Joseph University, Beirut, Lebanon</aff>
<author-notes>
<corresp id="corresp1-1533317512465667">Rami Bou Khalil, MD, Psychiatric Hospital of the Cross, Saint Joseph University, Jalledib, Beirut, Lebanon Email: <email>ramiboukhalil@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>8</issue>
<fpage>564</fpage>
<lpage>567</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Alzheimer’s disease (AD) is a neurodegenerative disease with no available disease-modifying drugs. However, it has been postulated that neurovascular damage is a primary occurrence in this disease. Neurovascular damage is the result of the presence of cardiovascular risk factor generating hypoxia, oxidative stress, and metabolic changes that activate the endothelial cells of the brain microvasculature in order to respond to the stress by the development of angiogenesis. This endothelial activation could lead to a secretion of many proinflammatory cytokines and growth factors, such as thrombin. Heparin and related oligosaccharides have been shown to be efficient in the improvement of symptoms of AD. Their efficacy may be limited by their nonselective inhibitory effect of thrombin’s activity. Direct thrombin inhibitors, such as dabigatran, might be efficient in the treatment of patients with AD because of their high selectivity for thrombin’s activity inhibition while having a safer side effects profile than heparin.</p>
</abstract>
<kwd-group>
<kwd>thrombin</kwd>
<kwd>thrombin inhibitors</kwd>
<kwd>Alzheimer’s disease</kwd>
<kwd>endothelial dysfunction</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1533317512465667">
<title>Introduction</title>
<p>Alzheimer’s disease (AD) is an age-related disorder characterized by progressive cognitive decline and dementia. Despite intense research efforts, effective disease-modifying therapies are still unavailable. Diagnostic criteria differentiate dementias between vascular dementia and AD despite the fact that mixed features are prevalent.<sup>
<xref ref-type="bibr" rid="bibr1-1533317512465667">1</xref>
</sup> Increasing literature supports a vascular–neuronal axis in AD because of the presence of common risk factors for both AD and cardiovascular diseases.<sup>
<xref ref-type="bibr" rid="bibr2-1533317512465667">2</xref>
</sup> Endothelial dysfunction is increasingly implicated in the development of neurodegenerative diseases with thrombin being an example of a vascular-derived factor possibly being at the basis of the physiopathology cascade resulting in AD.<sup>
<xref ref-type="bibr" rid="bibr3-1533317512465667">3</xref>
</sup>
</p>
</sec>
<sec id="section2-1533317512465667">
<title>Neurovascular Dysfunction and Inflammation in AD</title>
<p>In addition to a number of cerebrovascular abnormalities described in brains of patients with AD, there is increasing evidence that vascular risk factors are more commonly found in patients with AD possibly contributing to its pathogenesis.<sup>
<xref ref-type="bibr" rid="bibr4-1533317512465667">4</xref>
</sup> These risk factors may lead to cerebrovascular dysfunction. The clearance from brain to blood due to blood–brain barrier dysfunction contributes to enhanced β-amyloid levels in the brain.<sup>
<xref ref-type="bibr" rid="bibr5-1533317512465667">5</xref>
</sup> Inflammation may result from cerebrovascular injury which may explain why, according to one meta-analysis, nonsteroidal anti-inflammatory drugs have been shown to reduce AD incidence by an average of 58%.<sup>
<xref ref-type="bibr" rid="bibr6-1533317512465667">6</xref>
</sup> This inflammation leads to endothelial cell activation and secretion of many cytokines and growth factors that may by themselves perpetuate cerebrovascular injury, inflammation, and neuronal death.<sup>
<xref ref-type="bibr" rid="bibr2-1533317512465667">2</xref>,<xref ref-type="bibr" rid="bibr3-1533317512465667">3</xref>
</sup>
</p>
</sec>
<sec id="section3-1533317512465667">
<title>Role of Thrombin in Endothelial Activation of Patients With AD</title>
<p>Brain endothelial cells in culture have been shown to synthesize thrombin under stressful conditions, such as oxidative stress with an overexpression of thrombin messenger RNA in brain endothelial cells and microvessels of patients with AD.<sup>
<xref ref-type="bibr" rid="bibr7-1533317512465667">7</xref>,<xref ref-type="bibr" rid="bibr8-1533317512465667">8</xref>
</sup> A possible role for thrombin in proteolysis of tau under physiological and/or pathological conditions in human brains has been suggested along with the hypothesis that phosphorylation of tau inhibits proteolysis by thrombin, leading to its aggregation into insoluble fibrils.<sup>
<xref ref-type="bibr" rid="bibr9-1533317512465667">9</xref>
</sup> Furthermore, prothrombin and thrombin have been demonstrated to be expressed ubiquitously in brain cells and especially in neurofibrillary tangles and senile plaques, which suggests that thrombin may be involved in tau proteolysis and that failure to metabolize tau may lead to its aggregation in neurodegenerative diseases.<sup>
<xref ref-type="bibr" rid="bibr10-1533317512465667">10</xref>,<xref ref-type="bibr" rid="bibr11-1533317512465667">11</xref>
</sup> The hyperexpression of thrombin may lead to further endothelial activation and vascular inflammation. Exposure of neurons to thrombin results, experimentally, in significant apoptosis.<sup>
<xref ref-type="bibr" rid="bibr12-1533317512465667">12</xref>
</sup> Administration of thrombin directly into the rat brain results in neuronal cell death and cognitive deficits.<sup>
<xref ref-type="bibr" rid="bibr13-1533317512465667">13</xref>
</sup> Moreover, it has been demonstrated that thrombin exerts direct neurotoxicity.<sup>
<xref ref-type="bibr" rid="bibr14-1533317512465667">14</xref>
</sup> Furthermore, the proinflammatory effects of thrombin released from endothelial cells are also important because of the ability of thrombin to activate other central nervous system cells, such as microglia.<sup>
<xref ref-type="bibr" rid="bibr15-1533317512465667">15</xref>
</sup>
</p>
</sec>
<sec id="section4-1533317512465667">
<title>Role of Indirect Thrombin Inhibitors in AD</title>
<p>Thrombin plays a central role in the generation of a thrombus. Its principal function is to convert soluble fibrinogen into insoluble fibrin, while also stimulating platelet activation. It can be inhibited directly or indirectly by the binding of thrombin-inhibiting drugs to 1 or 2 of its 3 domains, the active site and exosites 1 and 2 (which is a heparin-binding domain).<sup>
<xref ref-type="bibr" rid="bibr16-1533317512465667">16</xref>
</sup> Traditional anticoagulants such as unfractionated heparin and low-molecular-weight heparin (LMWH) inhibit free thrombin in an indirect manner by forming a heparin–thrombin–antithrombin complex.<sup>
<xref ref-type="bibr" rid="bibr17-1533317512465667">17</xref>
</sup> The introduction of heparins in the treatment of AD was based on the hypothesis that heparins might improve the cerebral microcirculation through its antithrombotic effects.<sup>
<xref ref-type="bibr" rid="bibr18-1533317512465667">18</xref>
</sup> However, the hemorrhage potential and adverse effects of heparin held up momentarily its neurological applications despite the available data demonstrating its efficacy. For example, aged rats showed a significant partial reversal of age-related behavioral deficits following a high-molecular-weight glycosaminoglycans polysulfate administration.<sup>
<xref ref-type="bibr" rid="bibr19-1533317512465667">19</xref>
</sup> The neuroprotective effects of a LMWH-certoparin as demonstrated by significant decrease in the phosphorylated protein tau toxicity in an animal model mimicking the pathology of AD have been evaluated.<sup>
<xref ref-type="bibr" rid="bibr20-1533317512465667">20</xref>
</sup> Using the same animal model, the protective effects of a heparin oligosaccharide mixture on the brain after the injection of amyloid peptide into the amygdale have been demonstrated.<sup>
<xref ref-type="bibr" rid="bibr21-1533317512465667">21</xref>
</sup> The underlying mechanisms behind the effects of heparins on AD are not clear, but it is very likely that the anti-inflammatory effects in the central nervous system contribute to the overall mechanism explaining the efficacy heparins in AD. One of the components of this anti-inflammatory effect is generated by its antithrombin and anticoagulant activity.<sup>
<xref ref-type="bibr" rid="bibr22-1533317512465667">22</xref>
</sup>
</p>
</sec>
<sec id="section5-1533317512465667">
<title>Disadvantages of Indirect Thrombin Inhibitors</title>
<p>Heparins can simultaneously bind to both fibrin and thrombin and act as a bridge between them. This fibrin–heparin–thrombin complex occupies both thrombin exosites but leaves the active site enzymatically protected from inactivation which may result in further thrombus growth.<sup>
<xref ref-type="bibr" rid="bibr23-1533317512465667">23</xref>
</sup> In addition to its inability to neutralize fibrin-bound thrombin, heparin has other limitations such as binding to various plasma proteins, creating an unpredictable dose-dependent anticoagulant response, the need for routine dose-adjustments and anticoagulant monitoring, and finally heparin-induced thrombocytopenia (HIT).<sup>
<xref ref-type="bibr" rid="bibr24-1533317512465667">24</xref>
</sup>
</p>
</sec>
<sec id="section6-1533317512465667">
<title>Known Role of the Oral Direct Thrombin Inhibitor Dabigatran</title>
<p>Direct thrombin inhibitors bind directly to thrombin and do not require a cofactor such as antithrombin to exert their effect. They can inhibit both soluble thrombin and fibrin-bound thrombin. Other key advantages include a more predictable anticoagulant effect compared to heparins because of their lack of binding to other plasma proteins, an antiplatelet effect, and the absence of immune-mediated thrombocytopenia. Dabigatran etexilate is an orally active prodrug that is rapidly converted into dabigatran, a potent, reversible and specific direct thrombin inhibitor.<sup>
<xref ref-type="bibr" rid="bibr17-1533317512465667">17</xref>
</sup> In 2008, the European Medicines Agency granted marketing authorization for dabigatran etexilate for the prevention of thromboembolic disease following hip or knee replacement surgery; and in 2011, it was approved for use in patients with nonvalvular atrial fibrillation (AF) in the European Union while the US Food and Drug Administration approved dabigatran etexilate in 2010, for prevention of stroke in patients with nonvalvular AF.<sup>
<xref ref-type="bibr" rid="bibr17-1533317512465667">17</xref>,<xref ref-type="bibr" rid="bibr25-1533317512465667">25</xref>,<xref ref-type="bibr" rid="bibr26-1533317512465667">26</xref>
</sup> Dabigatran etexilate has undergone phase III, randomized controlled clinical trials for both venous thromboembolism (VTE) and stroke prevention in AF.<sup>
<xref ref-type="bibr" rid="bibr26-1533317512465667">26</xref>
</sup> According to the RE-COVER study, treatment with dabigatran at the dose of 150 mg twice a day (bid) has been shown to be noninferior for efficacy and at least as safe as warfarin at the usual international normalized ratio (INR) level in patients with acute VTE after an initial few days of parenteral anticoagulation.<sup>
<xref ref-type="bibr" rid="bibr27-1533317512465667">27</xref>
</sup> According to the RE-MEDY and RE-SONATE studies regarding the use of dabigatran in secondary VTE prevention, it has been found to be more effective than placebo and as effective as vitamin K antagonists, with a reduced risk of major bleeding but an increased incidence of acute coronary events.<sup>
<xref ref-type="bibr" rid="bibr28-1533317512465667">28</xref>
</sup> In the RE-LY study, 110 mg bid of dabigatran has been proven to be as effective as vitamin K antagonists in the prevention of strokes in patients with nonvalvular AF, with lower rates of major bleeding, while 150 mg bid associated with similar rates of major hemorrhage complications except for intracerebral hemorrhage.<sup>
<xref ref-type="bibr" rid="bibr29-1533317512465667">29</xref>,<xref ref-type="bibr" rid="bibr30-1533317512465667">30</xref>
</sup> However, there has been some concerns about the potential increase in major bleeding events with the administration of dabigatran etexilate in patients receiving it for stroke prevention because of AF.<sup>
<xref ref-type="bibr" rid="bibr31-1533317512465667">31</xref>
</sup> Reasons behind these adverse events were considered to be related to prescriber error (including the failure to allow the INR to fall below 2.0), impaired renal function, patient’s age, and complications arising from the lack of a reversal agent.<sup>
<xref ref-type="bibr" rid="bibr31-1533317512465667">31</xref>
</sup> Other direct thrombin inhibitors such as lepirudin, desirudin, bivalirudin, and agratroban are administered via parenteral routes for the treatment or prophylaxis of thrombosis complicating HIT, for the prevention of deep vein thrombosis following total hip replacement, for patients with unstable angina undergoing percutaneous transluminal angioplasty, for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI), and finally for patients undergoing PCI with a provisional usage of glycoprotein inhibitors.<sup>
<xref ref-type="bibr" rid="bibr17-1533317512465667">17</xref>
</sup>
</p>
</sec>
<sec id="section7-1533317512465667">
<title>Conclusion</title>
<p>Although heparin and related oligosaccharides are known to exhibit anti-inflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents, their major effect in AD could be more pertinently conveyed by their anti-inflammatory action. This anti-inflammatory action is considered to emanate from the endothelial cell activation in the brain microvasculature of patients with AD because of hypoxia, oxidative stress, and metabolic changes due to many cardiovascular risk factors. The inhibition of thrombin resulting from this endothelial cell activation may be one of the most important mechanisms explaining the efficacy of heparin in ameliorating AD symptoms. In this perspective, dabigatran may be more efficient and safer when administered to patients with AD.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1533317512465667">
<label>Declaration of Conflicting Interests</label>
<p>The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1533317512465667">
<label>Funding</label>
<p>The author received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1533317512465667">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Formichi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Parnetti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Radi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cevenini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dotti</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Federico</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>CSF biomarkers profile in CADASIL-A model of pure vascular dementia: usefulness in differential diagnosis in the dementia disorder</article-title>. <source>Int J Alzheimers Dis</source>. <year>2010</year>;<volume>2010</volume>:<fpage>959257</fpage>.</citation>
</ref>
<ref id="bibr2-1533317512465667">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grammas</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease</article-title>. <source>J Neuroinflammation</source>. <year>2011</year>;<volume>8</volume>:<fpage>26</fpage>.</citation>
</ref>
<ref id="bibr3-1533317512465667">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salmina</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Inzhutova</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Malinovskaya</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Petrova</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: neuronal and glial control</article-title>. <source>J Alzheimer Dis</source>. <year>2010</year>;<volume>22</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr4-1533317512465667">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Humpel</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?</article-title> <source>Exp Gerontol</source>. <year>2011</year>;<volume>46</volume>(<issue>4</issue>):<fpage>225</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr5-1533317512465667">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moser</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Humpel</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Blood-derived serum albumin contributes to neurodegeneration via astroglial stress fiber formation</article-title>. <source>Pharmacology</source>. <year>2007</year>;<volume>80</volume>(<issue>4</issue>):<fpage>286</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr6-1533317512465667">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szekely</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Thorne</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Zandi</surname>
<given-names>PP</given-names>
</name>
<etal/>
</person-group> <article-title>Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review</article-title>. <source>Neuroepidemiology</source>. <year>2004</year>;<volume>23</volume>(<issue>4</issue>):<fpage>159</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr7-1533317512465667">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wall</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Grammas</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease</article-title>. <source>Am J Pathol</source>. <year>2010</year>;<volume>176</volume>(<issue>4</issue>):<fpage>1600</fpage>–<lpage>1606</lpage>.</citation>
</ref>
<ref id="bibr8-1533317512465667">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grammas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Samany</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Thirumangalakudi</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis</article-title>. <source>J Alzheimers Dis</source>. <year>2006</year>;<volume>9</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr9-1533317512465667">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>McGeer</surname>
<given-names>PL</given-names>
</name>
</person-group>. <article-title>Proteolysis of non-phosphorylated and phosphorylated tau by thrombin</article-title>. <source>J Biol Chem</source>. <year>2005</year>;<volume>280</volume>(<issue>7</issue>):<fpage>5145</fpage>–<lpage>5153</lpage>.</citation>
</ref>
<ref id="bibr10-1533317512465667">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miklossy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klegeris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>McGeer</surname>
<given-names>PL</given-names>
</name>
</person-group>. <article-title>Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2006</year>;<volume>65</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr11-1533317512465667">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reimann-Philipp</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Ovase</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Weigel</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Grammas</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Mechanisms of cell death in primary cortical neurons and PC12 cells</article-title>. <source>J Neurosci Res</source>. <year>2001</year>;<volume>64</volume>(<issue>6</issue>):<fpage>654</fpage>–<lpage>660</lpage>.</citation>
</ref>
<ref id="bibr12-1533317512465667">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akiyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McGeer</surname>
<given-names>PL</given-names>
</name>
</person-group>. <article-title>Thrombin accumulation in patients with Alzheimer’s disease</article-title>. <source>Neurosci Lett</source>. <year>1992</year>;<volume>146</volume>(<issue>2</issue>):<fpage>152</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr13-1533317512465667">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mhatre</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kashani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Adesina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grammas</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Thrombin, a mediator of neurotoxicity and memory impairment</article-title>. <source>Neurobiol Aging</source>. <year>2004</year>;<volume>25</volume>(<issue>6</issue>):<fpage>783</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr14-1533317512465667">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>BK</given-names>
</name>
</person-group>. <article-title>Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase</article-title>. <source>J Neurosci Res</source>. <year>2008</year>;<volume>86</volume>(<issue>5</issue>):<fpage>1053</fpage>–<lpage>1063</lpage>.</citation>
</ref>
<ref id="bibr15-1533317512465667">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Thrombin-induced microglial activation contributes to the degeneration of nigral dopaminergic neurons in vivo</article-title>. <source>Neurosci Bull</source>. <year>2008</year>;<volume>24</volume>(<issue>2</issue>):<fpage>66</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr16-1533317512465667">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tulinsky</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Molecular interactions of thrombin</article-title>. <source>Semin Thromb Hemost</source>. <year>1996</year>;<volume>22</volume>(<issue>2</issue>):<fpage>117</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr17-1533317512465667">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Brien</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Mureebe</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Direct thrombin inhibitors</article-title>. <source>J Cardiovasc Pharmacol Ther</source>. <year>2012</year>;<volume>17</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr18-1533317512465667">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santini</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>A general practice trial of Ateroid 200 in 8,776 patients with chronic senile cerebral insufficiency</article-title>. <source>Mod Probl Pharmacopsychiatry</source>. <year>1989</year>;<volume>23</volume>:<fpage>95</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr19-1533317512465667">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorens</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Guschwan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>van de Kar</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fareed</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Behavioral, endocrine, and neurochemical effects of sulfomucopolysaccharide treatment in the aged Fischer 344 male rat</article-title>. <source>Sem Thromb Hemost</source>. <year>1991</year>;<volume>17</volume>(<issue>suppl 2</issue>):<fpage>S164</fpage>–<lpage>S173</lpage>.</citation>
</ref>
<ref id="bibr20-1533317512465667">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walzer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lorens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hejna</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Low molecular weight glycosaminoglycan blockade of betaamyloid induced neuropathology</article-title>. <source>Eur J Pharmacol</source>. <year>2002</year>;<volume>445</volume>(<issue>3</issue>):<fpage>211</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr21-1533317512465667">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dudas</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cornelli</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group> <article-title>Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain</article-title>. <source>Neurobiol Aging</source>. <year>2002</year>;<volume>23</volume>(<issue>1</issue>):<fpage>97</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr22-1533317512465667">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esmon</surname>
<given-names>CT</given-names>
</name>
</person-group>. <article-title>New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins</article-title>. <source>J Exp Med</source>. <year>2002</year>;<volume>196</volume>(<issue>5</issue>):<fpage>561</fpage>–<lpage>564</lpage>.</citation>
</ref>
<ref id="bibr23-1533317512465667">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weitz</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hudoba</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombinindependent inhibitors</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>97</volume>(<issue>6</issue>):<fpage>544</fpage>–<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr24-1533317512465667">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bates</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Weitz</surname>
<given-names>JI.</given-names>
</name>
</person-group> <article-title>The mechanism of action of thrombin inhibitors</article-title>. <source>J Invasive Cardiol</source>. <year>2000</year>;<volume>12</volume>(<issue>suppl F</issue>):<fpage>27F</fpage>–<lpage>32F</lpage>.</citation>
</ref>
<ref id="bibr25-1533317512465667">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turpie</surname>
<given-names>AG</given-names>
</name>
</person-group>. <article-title>New oral anticoagulants in atrial fibrillation</article-title>. <source>Eur Heart J</source>. <year>2008</year>;<volume>29</volume>(<issue>2</issue>):<fpage>155</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr26-1533317512465667">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tripodi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Palareti</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation</article-title>. <source>J Intern Med</source>. <year>2012</year>;<volume>271</volume>(<issue>6</issue>):<fpage>554</fpage>–<lpage>565</lpage>.</citation>
</ref>
<ref id="bibr27-1533317512465667">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kearon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kakkar</surname>
<given-names>AK</given-names>
</name>
<etal/>
</person-group> <article-title>RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>(<issue>24</issue>):<fpage>2342</fpage>–<lpage>2352</lpage>.</citation>
</ref>
<ref id="bibr28-1533317512465667">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulman</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Treatment of venous thromboembolism with dabigatran</article-title>. <source>Curr Opin Pulm Med</source>. <year>2012</year>;<volume>18</volume>(<issue>5</issue>):<fpage>410</fpage>–<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr29-1533317512465667">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connolly</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Ezekowitz</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>(<issue>12</issue>):<fpage>1139</fpage>–<lpage>1151</lpage>.</citation>
</ref>
<ref id="bibr30-1533317512465667">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connolly</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Ezekowitz</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reilly</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Wallentin</surname>
<given-names>L.</given-names>
</name>
</person-group> <article-title>Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>(<issue>19</issue>):<fpage>1875</fpage>–<lpage>1876</lpage>.</citation>
</ref>
<ref id="bibr31-1533317512465667">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harper</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Merriman</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Bleeding risk with dabigatran in the frail elderly</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>(<issue>9</issue>):<fpage>864</fpage>–<lpage>866</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>